Cargando…

Screening of Potential Breast Cancer Inhibitors through Molecular Docking and Molecular Dynamics Simulation

Cyclooxygenase-2 (COX-2) is a key enzyme involved in overexpression in several human cancerous diseases including breast cancer. By performing efficient virtual screening in a series of active molecules or compounds from the Maybridge, NCI (National Cancer Institute), and Enamine databases, potentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandi, Sangavi, Kulanthaivel, Langeswaran, Subbaraj, Gowtham Kumar, Rajaram, Sangeetha, Subramanian, Senthilkumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256436/
https://www.ncbi.nlm.nih.gov/pubmed/35800218
http://dx.doi.org/10.1155/2022/3338549
_version_ 1784741113357139968
author Pandi, Sangavi
Kulanthaivel, Langeswaran
Subbaraj, Gowtham Kumar
Rajaram, Sangeetha
Subramanian, Senthilkumar
author_facet Pandi, Sangavi
Kulanthaivel, Langeswaran
Subbaraj, Gowtham Kumar
Rajaram, Sangeetha
Subramanian, Senthilkumar
author_sort Pandi, Sangavi
collection PubMed
description Cyclooxygenase-2 (COX-2) is a key enzyme involved in overexpression in several human cancerous diseases including breast cancer. By performing efficient virtual screening in a series of active molecules or compounds from the Maybridge, NCI (National Cancer Institute), and Enamine databases, potential identification of COX-2 inhibitors could lead to new prognostic strategies in the treatment of breast cancer. Based on a 50% structural similitude, compounds were chosen as the inductive model of COX-2 inhibitions from these databases. Selected compounds were filtered and tested with Lipinski's rule of five followed by absorption, distribution, metabolism, and excretion (ADME) properties. Subsequently, molecular docking was performed to achieve accuracy in screening and also to find an interactive mechanism between hit compounds with their respective binding sites. Simultaneously, molecular simulations of top-scored compounds were selected and coded such as Maybridge_55417, NCI_30552, and Enamine_62410. Chosen compounds were analyzed and interpreted with COX-2 affinity. Results endorsed that hydrophobic affinity and optimum hydrogen bonds were the forces driven in the interactive mechanism of in silico hits compounds with COX-2 and can be used as efficient alternative therapeutic agents targeting deleterious breast cancer. With these in silico findings, compounds identified may prevent the action of the COX-2 enzyme and thereby diminish the incidence of breast cancer.
format Online
Article
Text
id pubmed-9256436
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-92564362022-07-06 Screening of Potential Breast Cancer Inhibitors through Molecular Docking and Molecular Dynamics Simulation Pandi, Sangavi Kulanthaivel, Langeswaran Subbaraj, Gowtham Kumar Rajaram, Sangeetha Subramanian, Senthilkumar Biomed Res Int Research Article Cyclooxygenase-2 (COX-2) is a key enzyme involved in overexpression in several human cancerous diseases including breast cancer. By performing efficient virtual screening in a series of active molecules or compounds from the Maybridge, NCI (National Cancer Institute), and Enamine databases, potential identification of COX-2 inhibitors could lead to new prognostic strategies in the treatment of breast cancer. Based on a 50% structural similitude, compounds were chosen as the inductive model of COX-2 inhibitions from these databases. Selected compounds were filtered and tested with Lipinski's rule of five followed by absorption, distribution, metabolism, and excretion (ADME) properties. Subsequently, molecular docking was performed to achieve accuracy in screening and also to find an interactive mechanism between hit compounds with their respective binding sites. Simultaneously, molecular simulations of top-scored compounds were selected and coded such as Maybridge_55417, NCI_30552, and Enamine_62410. Chosen compounds were analyzed and interpreted with COX-2 affinity. Results endorsed that hydrophobic affinity and optimum hydrogen bonds were the forces driven in the interactive mechanism of in silico hits compounds with COX-2 and can be used as efficient alternative therapeutic agents targeting deleterious breast cancer. With these in silico findings, compounds identified may prevent the action of the COX-2 enzyme and thereby diminish the incidence of breast cancer. Hindawi 2022-06-28 /pmc/articles/PMC9256436/ /pubmed/35800218 http://dx.doi.org/10.1155/2022/3338549 Text en Copyright © 2022 Sangavi Pandi et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Pandi, Sangavi
Kulanthaivel, Langeswaran
Subbaraj, Gowtham Kumar
Rajaram, Sangeetha
Subramanian, Senthilkumar
Screening of Potential Breast Cancer Inhibitors through Molecular Docking and Molecular Dynamics Simulation
title Screening of Potential Breast Cancer Inhibitors through Molecular Docking and Molecular Dynamics Simulation
title_full Screening of Potential Breast Cancer Inhibitors through Molecular Docking and Molecular Dynamics Simulation
title_fullStr Screening of Potential Breast Cancer Inhibitors through Molecular Docking and Molecular Dynamics Simulation
title_full_unstemmed Screening of Potential Breast Cancer Inhibitors through Molecular Docking and Molecular Dynamics Simulation
title_short Screening of Potential Breast Cancer Inhibitors through Molecular Docking and Molecular Dynamics Simulation
title_sort screening of potential breast cancer inhibitors through molecular docking and molecular dynamics simulation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256436/
https://www.ncbi.nlm.nih.gov/pubmed/35800218
http://dx.doi.org/10.1155/2022/3338549
work_keys_str_mv AT pandisangavi screeningofpotentialbreastcancerinhibitorsthroughmoleculardockingandmoleculardynamicssimulation
AT kulanthaivellangeswaran screeningofpotentialbreastcancerinhibitorsthroughmoleculardockingandmoleculardynamicssimulation
AT subbarajgowthamkumar screeningofpotentialbreastcancerinhibitorsthroughmoleculardockingandmoleculardynamicssimulation
AT rajaramsangeetha screeningofpotentialbreastcancerinhibitorsthroughmoleculardockingandmoleculardynamicssimulation
AT subramaniansenthilkumar screeningofpotentialbreastcancerinhibitorsthroughmoleculardockingandmoleculardynamicssimulation